Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alkotinib
- Development stage
- Phase 2
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Alkotinib is an orally available small molecule inhibitor targeting multiple kinases, most notably the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1). It binds to and inhibits both wild-type and mutant forms of ALK and ROS1—including fusion proteins—thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival. Alkotinib has demonstrated potential antineoplastic activity in preclinical models. The drug was developed by Suzhou Zelgen Biopharmaceuticals primarily for the treatment of non-small cell lung cancer (NSCLC) with ALK or ROS1 alterations[1][2][3].
- Brand names
- alkotinib
- Other names
- ocatinibZG0418ZG-0418ZG 0418
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on alkotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alkotinib.